Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line

GALECTIN THERAPEUTICS INC

FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.
Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.
Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.
Existing credit facilities also extended; company expects funding through at least March 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.